Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2021, Original papers
2021

Changing physicians’ attitudes regarding anticoagulant therapy for novel coronavirus infection in 2021: 616.411-003.971

Original papers
Published 2021-11-30
Eugene Roitman
Pirogov Russian National Research Medical University, Health Ministry of Russian Federation; 1 Ostrovityanova Str., Moscow 117997, Russia; Research Center of Neurology; 80 Volokolamskoe Shosse, Moscow 125367, Russia
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации; Россия, 117997 Москва, ул. Островитянова, 1; ФГБНУ «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80
Sergey Markin
Saint Petersburg Clinical Hospital, Russian Academy of Sciences; 72, Lit. A, Toreza Avenue, Saint Petersburg 194017, Russia
ФГБУЗ «Санкт-Петербургская клиническая больница Российской академии наук»; Россия, 194017 Санкт-Петербург, проспект Тореза, 72, Лит. А
Pavel Kravtsov
Samara State Medical University, Health Ministry of Russian Federation; 89 Chapaevskaya Str., Samara 443099, Russia
ФГБОУ ВО «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Россия, 443099 Самара, ул. Чапаевская, 89
Konstantin Mazayshvili
Surgut State University; 1 Lenin Avenue, Surgut 628412, Russia
БУ ВО Ханты-Мансийского автономного округа — Югры «Сургутский государственный университет»; Россия, 628412 Сургут, проспект Ленина, 1

Keywords

COVID‐19
thromboembolic complications
thrombotic complications
anticoagulant therapy
  Full Text

Abstract

Summary. Background. Despite a set of anti-epidemic measures, including mass vaccination, the spread of COVID-19-infection in the second half of 2021 continues. This is largely due to the emergence of new, more aggressive strains. One way or another, entry of SARS-CoV-2 virus into human body is still accompanied by development of COVID-19-associated coagulopathy realized in various thrombotic complications. Current clinical guidelines, already the 12th revision, describe the main approaches to treatment and prevention of venous thromboembolic complications, but their implementation is not always possible. Despite the increasing awareness of clinicians concerning pathogenetic aspects of infectious process development, a significant number of deviations and disorders, including those of systemic nature, still occur in real practice largely due to excessive desire to prevent some of them. Objectives: to study real clinical practice changes in treatment and prevention of thrombotic complications in patients with new COVID-19-infection. Materials/Methods. The work was based on two anonymous surveys conducted in February and August 2021 with the participation of 223 and 131 physicians treating patients with chronic and acute vascular diseases, respectively. The questionnaires included 17 questions describing physicians’ attitudes regarding treatment choices, use of pharmaceuticals, and methods of hemostasis monitoring. Results. The results of the questionnaires revealed a continuing high degree of aware- ness among the medical community about the increased risk of thrombotic complications in COVID-19 and the need to correct coagulopathy by prescribing adequate anticoagulant therapy (ACT). Low molecular weight heparins (LMWHs) retain the highest degree of confidence among respondents in inpatient ACT, although the number of physicians recommending new oral anticoag- ulants (NOACs) is increasing, despite the lack of high-quality randomized trials confirming their effectiveness. There has been an increase in respondents’ awareness of issues related to hemostasis laboratory control. Conclusions. The results obtained indicate the need to continue the information campaign regarding the prevention of COVID-19-coagulopathy among healthcare workers.

References:

  1. World Meter Corona Virus Update (Live). Available at: https:// www.worldometers.info/coronavirus/.
  2. Wu Z., McGoogan J.M.M. Characteristics of and important les- sons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese cen- ter for disease control and prevention. JAMA. 2020;323(13):1239– DOI: 10.1001/jama.2020.2648.
  3. Roitman E.V., Vavilova T.V., Markin S.M. et al. The realities of the anticoagulant therapy using in COVID-19. Tromboz, gemostaz i reologiya. 2021;(1):18–25. (In Russ.). DOI: 10.25555/THR.2021.1.0957.
  4. Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T. Description and proposed management of the acute COVID-19 cardiovascu- lar syndrome. Circulation. 2020;141(23):1903–14. DOI: 10.1161/cir- culationaha.120.047349.
  5. Chauhan A.J., Wiffen L.J., Brown T.P. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020;18(9):2110–7. DOI: 10.1111/jth.14981. 

  6. 
Kuznetsov S. I., Shestakov E. A., Zhiburt E. B. Coagulopathy in COVID-19 infection. Tromboz, gemostaz i reologiya. 2020;(4):31– 4. (In Russ.). DOI: 10.25555/THR.2020.4.0942. 

  7. Violi F., Pastori D., Cangemi R. et al. Hypercoagulation and anti- thrombotic treatment in coronavirus 2019: a new challenge. Thromb Haemost. 2020;120(6):949–56. DOI: 10.1055/s-0040–1710317. 

  8. Del Sole F., Farcomeni A., Loffredo L. et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Investig. 2020;50(10): e13378. DOI: 10.1111/eci.13378. 

  9. Spyropoulos A.C., Levy J.H., Ageno W. et al. Scientific and stan- dardization committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembo- lism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859–65. DOI:10.1111/jth.14929. 

  10. Zhai Z., Li C., Chen Y. et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infec- tion: a consensus statement before guidelines. Thromb Haemost. 
2020;120(6):937–48. DOI: 10.1055/s-0040–1710019.
  11. 
Temporary guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 12 (21.09.2021). Mos- cow: Health Ministry of Russian Federation, 2021. 232 рp. (In Russ.).
  12. Mousa S. A., Petersen L. J. Anti-cancer properties of low- molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009;102(2):258–67. DOI: 10.1160/TH08–12–0832.
  13. van der Wall S.J., Klok F.A., den Exter P.L. et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost. 2017;15(1):74–9. DOI: 10.1111/ jth.13563.
  14. Gonzalez-Ochoa A.J., Raffetto J.D., Hernández J.D. et al. Sulode- xide in the treatment of patients with early stages of COVID-19: a randomized controlled trial. Thromb Haemost. 2021;121(7):944– 54. DOI: 10.1101/2020.12.04.20242073.
  15. Connors J.M., Lev, J.H. Thromboinflammation and the hyperco- agulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–61. DOI: 10.1111/jth.14849.